Drug Approval | December 18, 2023
Zydus receives final approval from the USFDA for Lacosamide Tablets
Lacosamide is indicated to treat partial-onset seizures
Lacosamide is indicated to treat partial-onset seizures
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
Through the use of robotic assisted orthopaedic surgeries, the success rate is close to 98%
Digital success is contingent on the way a company organizes itself around technology
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
To create leading company developing medicines targeting metalloenzymes
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
Subscribe To Our Newsletter & Stay Updated
